Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.
about
Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure
P2860
Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@en
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@nl
type
label
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@en
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@nl
prefLabel
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@en
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@nl
P2093
P2860
P1433
P1476
Economic impact of disease pro ...... in classical Hodgkin lymphoma.
@en
P2093
Christopher A Yasenchak
Debra A Patt
Debra Rembert
Wan-Yu Tseng
P2860
P304
P356
10.3109/10428194.2015.1030639
P577
2015-04-10T00:00:00Z